Objective To study the clinical application value of HE4 and CA125 in qualitative distinctions of pelvic mass. Methods 100 cases of ovarian cancer and 100 cases of benign ovarian tumor from March 2012 to March 2014 in Women and Children's Medical Center of Guangzhou City (“our hospital” for short) were enrolled, and they were divid-ed into ovarian cancer group and benign tumor group respectively, healthy subjects received physical examination in the same period in our hospital were enrolled as healthy control group. Then serum HE4 and CA125 content were com-pared, and the sensitivity, specificity, positive predictive value, negative predictive value were analyzed. Results There were no statistically difference of serum HE4 and CA125 between benign ovarian cancer group and healthy control group (P>0.05);the serum HE4 and CA125 levels of ovarian cancer group [(154.56±20.41)μmol/L, (251.52±39.52) U/mL] were significantly higher than benign ovarian tumor group [(35.52±5.62)μmol/L, (48.52±1.94) U/mL] and the healthy con-trol group [(33.48±4.95) μmol/L, (42.48±5.62) U/mL], the differences were statistically significant (t=57.662, 56.241;50.97, 52.368; all P < 0.01); HE4 combined with CA125 detection sensitivity, specificity, positive predictive value, negative predictive value (94%, 98%, 97.92%, 94.23%) were significantly higher than separate detection HE4 (69%, 64%, 65.71, 67.37%), CA125 (59%, 68%, 65.84, 62.39%), the differences were statistically significant (χ2=20.726, 34.070;37.557, 31.893; 33.920, 34.368; 23.669, 31.685; all P< 0.01); serum CA125 and HE4 content of different TNM stage patients were different, as TNM stage increasing, CA125 and HE4 content were higher. Conclusion HE4 and CA125 are helpful to identity property of pelvic mass and diagnose ovarian cancer and benign ovarian tumor and have ideal sensitivity and specificity.%目的：研究人附睾蛋白4(HE4)及癌抗原125(CA125)在盆腔包块性质鉴别中的临床应用价值。方法将2012年3月~2014年3月广州市妇女儿童医疗中心(以下简称“我院”)收治的卵巢癌和卵巢良性肿瘤患者各100例纳入研究，将其分别作为卵巢癌组和卵巢良性肿瘤组，同时将同期在我院体检的健康者纳入研究的健康对照组。比较三组受试者的血清HE4及CA125，分析灵敏度、特异性、阳性预测值、阴性预测值。结果卵巢良性肿瘤组与健康对照组患者的血清HE4、CA125含量比较，差异无统计学意义(P>0.05)；卵巢癌组血清HE4和CA125[(154.56±20.41)μmol/L、(251.52±39.52)U/mL]含量高于卵巢良性肿瘤组[(35.52±5.62)μmol/L、(48.52±1.94)U/mL]和健康对照组[(33.48±4.95)μmol/L、(42.48±5.62)U/mL]，差异均有高度统计学意义(t=57.662、56.241；50.97、52.368；均P<0.01)；HE4、CA125联合检测的灵敏度、特异性、阳性预测值、阴性预测值(94%、98%、97.92%、94.23%)均高于单独检测，差异均有高度统计学意义(χ2=20.726、34.070；37.557、31.893；33.920、34.368；23.669、31.685；均P<0.01)；不同TNM分期患者血清CA125和HE4含量比较，差异均有统计学意义(P<0.05)，且TNM分期越高、CA125和HE4含量越高。结论 HE4及CA125有助于鉴别盆腔包块性质，诊断卵巢癌和卵巢良性肿瘤，具有较为理想的灵敏度和特异性。
展开▼
